599 related articles for article (PubMed ID: 29078760)
1. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
Kumar S; Chowdhury S; Kumar S
BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
[TBL] [Abstract][Full Text] [Related]
2. Biaryl scaffold-focused virtual screening for anti-aggregatory and neuroprotective effects in Alzheimer's disease.
Khalid S; Zahid MA; Ali H; Kim YS; Khan S
BMC Neurosci; 2018 Nov; 19(1):74. PubMed ID: 30424732
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking and molecular dynamics approach to identify potential compounds in
Tung BT; Hang TTT; Kim NB; Nhung NH; Linh VK; Thu DK
J Complement Integr Med; 2022 Dec; 19(4):955-965. PubMed ID: 35621378
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
Barai P; Raval N; Acharya S; Borisa A; Bhatt H; Acharya N
Behav Brain Res; 2019 Jan; 356():18-40. PubMed ID: 30118774
[TBL] [Abstract][Full Text] [Related]
5. Sarsasapogenin: A steroidal saponin from Asparagus racemosus as multi target directed ligand in Alzheimer's disease.
Kashyap P; Muthusamy K; Niranjan M; Trikha S; Kumar S
Steroids; 2020 Jan; 153():108529. PubMed ID: 31672628
[TBL] [Abstract][Full Text] [Related]
6. Identification of Butyrylcholinesterase and Monoamine Oxidase B Targeted Ligands and their Putative Application in Alzheimer's Treatment: A Computational Strategy.
Jabir NR; Rehman MT; Tabrez S; Alserihi RF; AlAjmi MF; Khan MS; Husain FM; Ahmed BA
Curr Pharm Des; 2021; 27(20):2425-2434. PubMed ID: 33634754
[TBL] [Abstract][Full Text] [Related]
7. Repurposing of FDA-approved drugs as dual-acting MAO-B and AChE inhibitors against Alzheimer's disease: An in silico and in vitro study.
Mateev E; Kondeva-Burdina M; Georgieva M; Zlatkov A
J Mol Graph Model; 2023 Jul; 122():108471. PubMed ID: 37087882
[TBL] [Abstract][Full Text] [Related]
8. Repurposing of phyto-ligand molecules from the honey bee products for Alzheimer's disease as novel inhibitors of BACE-1: small molecule bioinformatics strategies as amyloid-based therapy.
Nisa N; Rasmita B; Arati C; Uditraj C; Siddhartha R; Dinata R; Bhanushree B; Bidanchi RM; Manikandan B; Laskar SA; Abinash G; Pori B; Roy VK; Gurusubramanian G
Environ Sci Pollut Res Int; 2023 Apr; 30(17):51143-51169. PubMed ID: 36808033
[TBL] [Abstract][Full Text] [Related]
9. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Small Molecule PARKIN Activator from Antipsychotic/Anti-neuropsychiatric Drugs as Therapeutics for PD: an In Silico Repurposing Approach.
Ibrahim A; Ipinloju N; Atasie NH; Babalola RM; Muhammad SA; Oyeneyin OE
Appl Biochem Biotechnol; 2023 Oct; 195(10):5980-6002. PubMed ID: 36735144
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
12. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
Shoaib M; Kamal MA; Rizvi SMD
Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
[TBL] [Abstract][Full Text] [Related]
13. Novel Molecular Hybrids of
Sharma P; Tripathi A; Tripathi PN; Singh SS; Singh SP; Shrivastava SK
ACS Chem Neurosci; 2019 Oct; 10(10):4361-4384. PubMed ID: 31491074
[TBL] [Abstract][Full Text] [Related]
14. Combined QSAR, molecular docking and molecular dynamics study on new Acetylcholinesterase and Butyrylcholinesterase inhibitors.
Daoud I; Melkemi N; Salah T; Ghalem S
Comput Biol Chem; 2018 Jun; 74():304-326. PubMed ID: 29747032
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, Molecular Docking, and Cholinesterase Inhibitory Potential of Phthalimide-Dithiocarbamate Hybrids as New Agents for Treatment of Alzheimer's Disease.
Asadi M; Ebrahimi M; Mohammadi-Khanaposhtani M; Azizian H; Sepehri S; Nadri H; Biglar M; Amanlou M; Larijani B; Mirzazadeh R; Edraki N; Mahdavi M
Chem Biodivers; 2019 Nov; 16(11):e1900370. PubMed ID: 31523926
[TBL] [Abstract][Full Text] [Related]
16.
Galeana-Ascencio RA; Mendieta L; Limon DI; Gnecco D; Terán JL; Orea ML; Carrasco-Carballo A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175873
[TBL] [Abstract][Full Text] [Related]
17. Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).
Ferreira JPS; Albuquerque HMT; Cardoso SM; Silva AMS; Silva VLM
Eur J Med Chem; 2021 Oct; 221():113492. PubMed ID: 33984802
[TBL] [Abstract][Full Text] [Related]
18. New flavonoid -
Estrada-Valencia M; Herrera-Arozamena C; Pérez C; Viña D; Morales-García JA; Pérez-Castillo A; Ramos E; Romero A; Laurini E; Pricl S; Rodríguez-Franco MI
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):712-727. PubMed ID: 31852270
[TBL] [Abstract][Full Text] [Related]
19. Potential alternatives to current cholinesterase inhibitors: an
Kundu D; Dubey VK
Drug Dev Ind Pharm; 2021 Jun; 47(6):919-930. PubMed ID: 34219594
[TBL] [Abstract][Full Text] [Related]
20. Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy.
Zagórska A; Jaromin A
Molecules; 2020 Jul; 25(15):. PubMed ID: 32717806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]